Metabolic reprogramming and cancer progression

作者：B. Faubert, Ashley Solmonson, R. DeBerardinis · 发表于：Science · 年份：2020 · DOI：10.1126/science.aaw5473 · 被引用次数：2304 · 研究领域：Medicine

Metabolism as cancer progresses Numerous cancer-specific alterations in metabolism have been identified but have not yet resulted in an effective anti cancer therapeutic. In a Review, Faubert et al. discuss how metabolism changes as cancer develops from a small, premalignant lesion to an aggressive primary tumor and then metastasizes. Metabolic vulnerabilities likely change with cancer progression, making the identification of general cancer-associated metabolic features difficult. The authors propose that a more targeted approach to tissues and vulnerabilities identified in patients may be more effective. Science, this issue p. eaaw5473 BACKGROUND Metabolic reprogramming is a hallmark of malignancy first recognized a century ago. In some cases, reprogrammed metabolic activities can be exploited to diagnose, monitor, and treat cancer. Stereotyped metabolic activities in cultured cancer cells—notably, aerobic glycolysis, glutamine catabolism, macromolecular synthesis, and redox homeostasis—support the requirements of exponential growth and proliferation. These pathways are under cell-autonomous control by oncogenic signaling and transcriptional networks. This has produced the widespread perception that a core set of fixed metabolic dependencies will prove to be excellent therapeutic targets across diverse cancer types. Several metabolic inhibitors designed to target these pathways have advanced into clinical trials. ADVANCES The past decade has brought numerous advances in our...